e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Novel pharmacological findings in the management of respiratory disorders
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Measures of nebulizer performance – Comparing like with like
R. Hatley, Y. Degtyareva, R. Potter (Chichester, United Kingdom)
Source:
Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Session:
Novel pharmacological findings in the management of respiratory disorders
Session type:
Thematic Poster Session
Number:
715
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Hatley, Y. Degtyareva, R. Potter (Chichester, United Kingdom). Measures of nebulizer performance – Comparing like with like. Eur Respir J 2013; 42: Suppl. 57, 715
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Inhaler preference comparing two alternative dual bronchodilator regimens
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Optimizing patient experience of nebulizer treatments
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
LATE-BREAKING ABSTRACT: Effect of inhalation profiles and throat geometries on predicted lung deposition of budesonide and formoterol (BF) when inhaled through two different devices
Source: International Congress 2014 – Innovative technology and techniques in respiratory function
Year: 2014
The performance of a new vibrating mesh prototype nebulizer for inhaled biodrugs
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Optimal adherence with inhaled corticosteroids is related to better health status
Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections
Year: 2015
Use of an electronic monitoring system to generate objective information on patients’ adherence to taking treatments of a novel inhaled tobramycin solution
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children
Year: 2013
Comparison of the
in vitro
performance of originator and generic drug-combination dry powder inhalers
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013
Delivery of medication by breath-actuated nebulizer (BAN) is similar when used with differing inhalation / exhalation ratios: A contrast to breath enhanced nebulizer (BEN) behavior
Source: International Congress 2014 – Respiratory symptoms in primary care populations
Year: 2014
Extent of inhaled drug deposition at variable inhaler inclination angles and airway geometries: An in-vivo study from a novel computational fluid dynamics model
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Effect of interval between actuations of albuterol HFA inhalers on their aerosol characteristics
Source: International Congress 2016 – Paediatric asthma: recurrent, persistent, or severe obstruction and lung function techniques
Year: 2016
GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
Preference, satisfaction and critical errors with Genuair
®
and Breezhaler
®
in patients with COPD
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Domiciliary nebuliser treatment: How should we assess the response to treatment?
Source: Annual Congress 2003 - Assessing airway function: practicalities and clinical applications
Year: 2003
Tiotropium respimat: Comparison of bronchodilator efficacy of 5 and 2.5 µg doses
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Validation of FEV
1
spirometric endpoints as a measure of the anti-inflammatory and bronchodilatory effects of fluticasone/formoterol combination therapy
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Real-life asthma impairment: SABA use depends on smoking phenotype
Source: Annual Congress 2013 –Treatment and management of asthma in primary care
Year: 2013
The influence of type of inhalation device on adherence of COPD patients to inhaled medication
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Observation of the knowledge and use of inhalers in children
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Mixed treatment analysis comparing tiotropium HandiHaler
®
and Respimat
®
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept